Teva is in advanced discussions around the sale of TAPI. We will provide a final update to the market alongside our Q3 results. While exclusive discussions are ongoing, issues remain, and there is no certainty that a deal will be reached.
You are about to leave the Teva Pharmaceuticals global website
The website you are about to access may be governed by different regional policies, regulations or advertising codes. Please be sure to read the privacy policy and terms of use of the websites that you visit.
Teva Pharmaceuticals is not responsible for the accuracy or compliance with laws of information on any third party websites.